このページの翻訳は実験的なもので、現在開発中です。お待ちしております
United Therapeutics マネジメント
マネジメント 基準チェック /24
United Therapeutics'の CEO はMartine Rothblattで、 Jan1996年に任命され、 の在任期間は 28.42年です。 の年間総報酬は$ 16.96Mで、 8.7%給与と91.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.46%を直接所有しており、その価値は$ 198.07M 。経営陣と取締役会の平均在任期間はそれぞれ15.2年と21.8年です。
主要情報
Martine Rothblatt
最高経営責任者
US$17.0m
報酬総額
| CEO給与比率 | 8.7% |
| CEO在任期間 | 28.7yrs |
| CEOの所有権 | 1.4% |
| 経営陣の平均在職期間 | 15.4yrs |
| 取締役会の平均在任期間 | 22yrs |
経営陣の近況
Recent updates
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27
United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
報酬と市場: Martineの 総報酬 ($USD 16.96M ) は、 US市場 ($USD 13.02M ) の同規模の企業の平均を上回っています。
報酬と収益: Martineの報酬は過去 1 年間で 20% 以上増加しました。
CEO（最高経営責任者
Martine Rothblatt (69 yo)
28.7yrs
在職期間
US$16,958,057
報酬
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 28.7yrs | US$16.96m | 1.45% $ 231.1m | |
| President & COO | 8.3yrs | US$9.81m | 0.0058% $ 923.6k | |
| CFO & Treasurer | 11.7yrs | US$6.05m | 0.011% $ 1.7m | |
| Executive VP | 28.7yrs | US$5.15m | 0.083% $ 13.2m | |
| Head of Investor Relations | no data | データなし | データなし | |
| Associate Vice President of Human Resources | no data | データなし | データなし | |
| Senior Vice President of Strategic Operations & Logistics | no data | データなし | データなし | |
| Executive VP of Technical Operations | 15.4yrs | データなし | データなし | |
| Executive Vice President of Product Development & Xenotransplantation | no data | データなし | データなし | |
| Senior VP & Chief Medical Officer | no data | データなし | データなし |
15.4yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: UTHRの経営陣は経験豊富で経験豊富です（平均在職期間は15.2年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 28.7yrs | US$16.96m | 1.45% $ 231.1m | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 22.7yrs | US$457.60k | 0.027% $ 4.3m | |
| Independent Director & Member of the Scientific Advisory Board | 22yrs | US$471.54k | 0.029% $ 4.7m | |
| Independent Director & Member of the Scientific Advisory Board | 22.7yrs | US$456.54k | 0.0039% $ 626.9k | |
| Independent Vice Chairman & Lead Independent Director | 21.9yrs | US$532.60k | 0.0045% $ 717.8k | |
| Independent Director | 21.2yrs | US$481.54k | 0.0094% $ 1.5m | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 22.7yrs | US$456.54k | 0.051% $ 8.1m | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 9.3yrs | US$488.66k | 0.017% $ 2.7m | |
| Independent Director | 15.4yrs | US$513.66k | 0.039% $ 6.2m |
22.0yrs
平均在職期間
76yo
平均年齢
経験豊富なボード: UTHRの 取締役会 は経験豊富で 経験豊富 です ( 21.8年の平均在任期間)。